Ensign Peak Advisors
MDGL icon

Ensign Peak Advisors’s Madrigal Pharmaceuticals MDGL Stock Holding History

Ensign Peak Advisors’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$473K Hold
881
– – ﹤0.01% 1002
2026
Q1 		$461K Sell
881
-50,129
-98% -$23.9M ﹤0.01% 987
2025
Q4 		$29.7M Sell
51,010
-2,257
-4% -$1.15M 0.05% 245
2025
Q3 		$24.4M Buy
53,267
+4,868
+10% +$1.82M 0.04% 282
2025
Q2 		$14.6M Hold
48,399
– – 0.03% 383
2025
Q1 		$16M Buy
48,399
+13,038
+37% +$4.28M 0.03% 347
2024
Q4 		$10.9M Buy
35,361
+19,627
+125% +$5.52M 0.02% 450
2024
Q3 		$3.34M Sell
15,734
-67,639
-81% -$17.3M 0.01% 763
2024
Q2 		$23.4M Sell
83,373
-8,845
-10% -$2.11M 0.04% 290
2024
Q1 		$24.6M Buy
92,218
+30,806
+50% +$7.26M 0.05% 284
2023
Q4 		$14.2M Buy
61,412
+10,365
+20% +$1.81M 0.03% 356
2023
Q3 		$7.45M Buy
51,047
+9,850
+24% +$1.85M 0.02% 465
2023
Q2 		$9.52M Buy
41,197
+13,421
+48% +$3.64M 0.02% 426
2023
Q1 		$6.73M Buy
+27,776
New +$7.57M 0.01% 492
2022
Q4 		– Sell
-4,580
Closed -$298K – 2039
2022
Q3 		$298K Sell
4,580
-8,508
-65% -$591K ﹤0.01% 1707
2022
Q2 		$937K Buy
13,088
+11,528
+739% +$847K ﹤0.01% 1141
2022
Q1 		$153K Hold
1,560
– – ﹤0.01% 1947
2021
Q4 		$132K Buy
+1,560
New +$128K ﹤0.01% 2012

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Ensign Peak Advisors's MDGL Position: Q2 2026 in Review

Ensign Peak Advisors held its Madrigal Pharmaceuticals (MDGL) position steady in Q2 2026 at 881 shares worth $473K. The position accounts for ﹤0.01% of the portfolio, ranked #1002.

Ensign Peak Advisors first reported a position in MDGL in Q4 2021 and has held it in 18 quarters since. The position peaked at $29.7M in Q4 2025. 414 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • Ensign Peak Advisors held 881 shares of Madrigal Pharmaceuticals worth $473K as of Q2 2026.
  • Ensign Peak Advisors left its Madrigal Pharmaceuticals share count unchanged in Q2 2026.
  • Madrigal Pharmaceuticals made up ﹤0.01% of Ensign Peak Advisors's portfolio in Q2 2026, its #1002 holding.
  • Ensign Peak Advisors first reported a position in Madrigal Pharmaceuticals in Q4 2021 and has held it in 18 quarters since.
  • Ensign Peak Advisors's Madrigal Pharmaceuticals position peaked at $29.7M in Q4 2025.
  • 414 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Ensign Peak Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.